Evaluation of Fixed Dose Combination of Glimepiride and Metformin in Chinese Type 2 Diabetes Patients Inadequately Controlled With Metformin

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 244 participants.

Also called NCT01457911

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 244 participants (enrolled count) (from the registry)
Sponsor
  • Sanofi Registry lists this organization as the lead sponsor
Registry
  • NCT NCT01457911
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
China (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01457911. Randomized; no masking; primary purpose treatment. Start 2011-10 (registry gives no type); primary completion 2013-02 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Evaluation of Fixed Dose Combination of Glimepiride and Metformin in Chinese Type 2 Diabetes Patients Inadequately Controlled With Metformin
Condition
Type 2 Diabetes Mellitus
Intervention (Drug)
Glimepiride and Metformin hydrochloride combination (HOE490)
Intervention (Drug)
Glimepiride (HOE490)
Lead sponsor
Sanofi (class: industry)

Record details

Record id
cardio:ct-nct01457911
Content hash
0206a5a762743c51a89f04026cca4e0a63455bf03cdc737d72877ce4b2587644